Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel Free LGVN Stock Alerts

Longeveron (LGVN) Competitors

Longeveron logo
$0.86 -0.01 (-0.78%)
Closing price 04:00 PM Eastern
Extended Trading
$0.87 +0.02 (+2.09%)
As of 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

LGVN vs. LONA, CYPH, GOSS, GANX, and ATYR

Should you be buying Longeveron stock or one of its competitors? The main competitors of Longeveron include Athira Pharma (LONA), Cypherpunk Technologies (CYPH), Gossamer Bio (GOSS), Gain Therapeutics (GANX), and aTyr Pharma (ATYR). These companies are all part of the "pharmaceutical products" industry.

How does Longeveron compare to Athira Pharma?

Longeveron (NASDAQ:LGVN) and Athira Pharma (NASDAQ:LONA) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Longeveron has a beta of -0.31, indicating that its share price is 131% less volatile than the S&P 500. Comparatively, Athira Pharma has a beta of 1.98, indicating that its share price is 98% more volatile than the S&P 500.

In the previous week, Longeveron had 4 more articles in the media than Athira Pharma. MarketBeat recorded 5 mentions for Longeveron and 1 mentions for Athira Pharma. Longeveron's average media sentiment score of -0.67 beat Athira Pharma's score of -1.74 indicating that Longeveron is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Longeveron
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Negative
Athira Pharma
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Very Negative

10.0% of Longeveron shares are owned by institutional investors. Comparatively, 57.1% of Athira Pharma shares are owned by institutional investors. 11.2% of Longeveron shares are owned by company insiders. Comparatively, 25.1% of Athira Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Athira Pharma has a net margin of 0.00% compared to Longeveron's net margin of -1,893.58%. Longeveron's return on equity of -199.79% beat Athira Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Longeveron-1,893.58% -199.79% -143.21%
Athira Pharma N/A -340.97%-209.91%

Longeveron presently has a consensus price target of $5.50, suggesting a potential upside of 542.45%. Athira Pharma has a consensus price target of $10.00, suggesting a potential upside of 3.84%. Given Longeveron's stronger consensus rating and higher possible upside, equities analysts clearly believe Longeveron is more favorable than Athira Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Longeveron
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Athira Pharma
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Longeveron has higher revenue and earnings than Athira Pharma. Athira Pharma is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Longeveron$1.20M16.60-$22.70M-$1.28N/A
Athira PharmaN/AN/A-$105.61M-$9.68N/A

Summary

Longeveron beats Athira Pharma on 10 of the 14 factors compared between the two stocks.

How does Longeveron compare to Cypherpunk Technologies?

Cypherpunk Technologies (NASDAQ:CYPH) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

Cypherpunk Technologies has higher earnings, but lower revenue than Longeveron. Longeveron is trading at a lower price-to-earnings ratio than Cypherpunk Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cypherpunk TechnologiesN/AN/A$4.82M$0.0715.29
Longeveron$1.20M16.60-$22.70M-$1.28N/A

Cypherpunk Technologies has a beta of -0.1, indicating that its stock price is 110% less volatile than the S&P 500. Comparatively, Longeveron has a beta of -0.31, indicating that its stock price is 131% less volatile than the S&P 500.

Longeveron has a consensus price target of $5.50, suggesting a potential upside of 542.45%. Given Longeveron's stronger consensus rating and higher probable upside, analysts clearly believe Longeveron is more favorable than Cypherpunk Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cypherpunk Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Longeveron
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

In the previous week, Longeveron had 4 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 5 mentions for Longeveron and 1 mentions for Cypherpunk Technologies. Cypherpunk Technologies' average media sentiment score of 0.75 beat Longeveron's score of -0.67 indicating that Cypherpunk Technologies is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cypherpunk Technologies
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Longeveron
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Negative

30.5% of Cypherpunk Technologies shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 4.3% of Cypherpunk Technologies shares are owned by company insiders. Comparatively, 11.2% of Longeveron shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Cypherpunk Technologies has a net margin of 0.00% compared to Longeveron's net margin of -1,893.58%. Cypherpunk Technologies' return on equity of -99.76% beat Longeveron's return on equity.

Company Net Margins Return on Equity Return on Assets
Cypherpunk TechnologiesN/A -99.76% -79.44%
Longeveron -1,893.58%-199.79%-143.21%

Summary

Cypherpunk Technologies beats Longeveron on 9 of the 15 factors compared between the two stocks.

How does Longeveron compare to Gossamer Bio?

Gossamer Bio (NASDAQ:GOSS) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

In the previous week, Gossamer Bio had 19 more articles in the media than Longeveron. MarketBeat recorded 24 mentions for Gossamer Bio and 5 mentions for Longeveron. Gossamer Bio's average media sentiment score of 0.11 beat Longeveron's score of -0.67 indicating that Gossamer Bio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gossamer Bio
0 Very Positive mention(s)
0 Positive mention(s)
24 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Longeveron
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Negative

Gossamer Bio has a beta of 2.15, meaning that its share price is 115% more volatile than the S&P 500. Comparatively, Longeveron has a beta of -0.31, meaning that its share price is 131% less volatile than the S&P 500.

Longeveron has lower revenue, but higher earnings than Gossamer Bio. Longeveron is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gossamer Bio$48.47M1.63-$170.37M-$0.75N/A
Longeveron$1.20M16.60-$22.70M-$1.28N/A

Gossamer Bio has a net margin of -351.49% compared to Longeveron's net margin of -1,893.58%. Gossamer Bio's return on equity of 0.00% beat Longeveron's return on equity.

Company Net Margins Return on Equity Return on Assets
Gossamer Bio-351.49% N/A -75.50%
Longeveron -1,893.58%-199.79%-143.21%

Gossamer Bio currently has a consensus price target of $5.43, indicating a potential upside of 1,515.65%. Longeveron has a consensus price target of $5.50, indicating a potential upside of 542.45%. Given Gossamer Bio's higher probable upside, equities analysts clearly believe Gossamer Bio is more favorable than Longeveron.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gossamer Bio
2 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.20
Longeveron
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 7.2% of Gossamer Bio shares are owned by company insiders. Comparatively, 11.2% of Longeveron shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Gossamer Bio beats Longeveron on 12 of the 16 factors compared between the two stocks.

How does Longeveron compare to Gain Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

In the previous week, Longeveron had 4 more articles in the media than Gain Therapeutics. MarketBeat recorded 5 mentions for Longeveron and 1 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 1.05 beat Longeveron's score of -0.67 indicating that Gain Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gain Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Longeveron
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Negative

Gain Therapeutics has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500. Comparatively, Longeveron has a beta of -0.31, meaning that its share price is 131% less volatile than the S&P 500.

Gain Therapeutics has higher earnings, but lower revenue than Longeveron. Gain Therapeutics is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gain TherapeuticsN/AN/A-$20.16M-$0.61N/A
Longeveron$1.20M16.60-$22.70M-$1.28N/A

Gain Therapeutics has a net margin of 0.00% compared to Longeveron's net margin of -1,893.58%. Longeveron's return on equity of -199.79% beat Gain Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Gain TherapeuticsN/A -237.54% -145.96%
Longeveron -1,893.58%-199.79%-143.21%

Gain Therapeutics currently has a consensus price target of $8.50, indicating a potential upside of 354.55%. Longeveron has a consensus price target of $5.50, indicating a potential upside of 542.45%. Given Longeveron's higher probable upside, analysts clearly believe Longeveron is more favorable than Gain Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gain Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Longeveron
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

12.0% of Gain Therapeutics shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 7.2% of Gain Therapeutics shares are owned by company insiders. Comparatively, 11.2% of Longeveron shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Gain Therapeutics beats Longeveron on 8 of the 15 factors compared between the two stocks.

How does Longeveron compare to aTyr Pharma?

Longeveron (NASDAQ:LGVN) and aTyr Pharma (NASDAQ:ATYR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

aTyr Pharma has a net margin of 0.00% compared to Longeveron's net margin of -1,893.58%. aTyr Pharma's return on equity of -99.87% beat Longeveron's return on equity.

Company Net Margins Return on Equity Return on Assets
Longeveron-1,893.58% -199.79% -143.21%
aTyr Pharma N/A -99.87%-74.41%

Longeveron currently has a consensus price target of $5.50, indicating a potential upside of 542.45%. aTyr Pharma has a consensus price target of $25.67, indicating a potential upside of 2,947.57%. Given aTyr Pharma's higher possible upside, analysts clearly believe aTyr Pharma is more favorable than Longeveron.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Longeveron
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
aTyr Pharma
1 Sell rating(s)
5 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Longeveron had 3 more articles in the media than aTyr Pharma. MarketBeat recorded 5 mentions for Longeveron and 2 mentions for aTyr Pharma. aTyr Pharma's average media sentiment score of 0.00 beat Longeveron's score of -0.67 indicating that aTyr Pharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Longeveron
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Negative
aTyr Pharma
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

10.0% of Longeveron shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 11.2% of Longeveron shares are owned by insiders. Comparatively, 5.8% of aTyr Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Longeveron has a beta of -0.31, indicating that its stock price is 131% less volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500.

Longeveron has higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Longeveron$1.20M16.60-$22.70M-$1.28N/A
aTyr Pharma$190K434.62-$74.12M-$0.79N/A

Summary

aTyr Pharma beats Longeveron on 9 of the 16 factors compared between the two stocks.

Get Longeveron News Delivered to You Automatically

Sign up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LGVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LGVN vs. The Competition

Export
MetricLongeveronMED IndustryMedical SectorNASDAQ Exchange
Market Cap$19.92M$3.40B$6.25B$11.87B
Dividend YieldN/A2.20%2.73%5.21%
P/E Ratio-0.6738.8529.0428.48
Price / Sales16.60155.54476.4860.89
Price / CashN/A57.8827.6236.52
Price / Book3.427.039.676.67
Net Income-$22.70M$23.62M$3.55B$332.64M
7 Day Performance-3.17%3.67%1.70%2.01%
1 Month Performance-19.99%7.17%5.62%9.19%
1 Year Performance-42.93%67.04%34.42%39.59%

Longeveron Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LGVN
Longeveron
1.4423 of 5 stars		$0.86
-0.8%		$5.50
+542.4%		N/A$19.92M$1.20MN/A20
LONA
Athira Pharma
0.7624 of 5 stars		$8.69
+4.1%		$10.00
+15.1%		N/A$81.60MN/AN/A40
CYPH
Cypherpunk Technologies
0.8292 of 5 stars		$0.91
-2.2%		N/AN/A$81.43MN/A12.9340
GOSS
Gossamer Bio
2.5197 of 5 stars		$0.34
-1.0%		$5.43
+1,474.0%		N/A$80.95M$48.47MN/A180
GANX
Gain Therapeutics
1.659 of 5 stars		$1.85
-5.1%		$8.50
+359.5%		N/A$78.14M$50KN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:LGVN) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel